A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Indian J Ophthalmol
;
2007 Nov-Dec; 55(6): 437-9
Artículo
en Inglés
| IMSEAR
| ID: sea-69682
ABSTRACT
Wet age-related macular degeneration and diabetic retinopathy are pathological consequences of vascular endothelial growth factor (VEGF) release as a reaction to deficiency of oxygen and nutrients in the macular cells. Conventional treatment modalities have been constrained by limited success. Convincing evidence exists that targeting VEGF signaling is a significant approach for the therapy of these ocular angiogenesis-dependent disorders. We have come a long way since the approval of the first angiogenesis inhibitors in medicine. The clinical use of these drugs has provided enormous tempo to clinical and pharmacological research. It has also significantly altered patient outcome and expectations. In the following brief, we will discuss the development and emergence of these drugs as well as the anticipated future course based on evidence.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Humanos
/
Resultado del Tratamiento
/
Inhibidores de la Angiogénesis
/
Factor A de Crecimiento Endotelial Vascular
/
Retinopatía Diabética
/
Aptámeros de Nucleótidos
/
Degeneración Macular
/
Anticuerpos Monoclonales
Idioma:
Inglés
Revista:
Indian J Ophthalmol
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS